<DOC>
	<DOC>NCT02662114</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the effectiveness of Tresiba® (insulin degludec) after switching basal insulin in a population with type 1 or type 2 diabetes mellitus. EU-TREAT (EUropean TREsiba AudiT)</brief_summary>
	<brief_title>Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Informed consent will be obtained before any studyrelated activities. Studyrelated activities are any data collection from the medical records of the patient Age at least 18 years at the time of Tresiba® initiation T1DM or insulintreated T2DM patients Switched to Tresiba® (with or without prandial insulin) after any basal insulin (with or without prandial insulin). Switch must have occurred at least 6 months prior to data collection and the patient may or may not be treated with Tresiba® at the time of patient selection Previously treated with any basal insulin (with or without prandial insulin) for at least 6 months prior to switching to Tresiba® At least one documented medical visit in the first 9 months after Tresiba® initiation Minimum available data at the time of Tresiba® initiation: age, type of diabetes, HbA1c (Glycated haemoglobin), duration of diabetes, duration and type of insulin treatment, medical followup at the study site of at least 1 year, and an eGFR (Estimated glomerular filtration rate )value in the last 12 months Previous participation in this study. Participation is defined as having signed the Informed Consent Participation in a diabetes clinical trial or receipt of any investigational medicinal product up to 12 months before or any time after the initiation of Tresiba® Current participation in another noninterventional study on insulin degludec (Tresiba®) Patients treated by continuous subcutaneous insulin infusion or premix insulin in the 6 months prior to receiving Tresiba®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>